WHO recommends twice-yearly HIV prevention injection

The World Health Organization (WHO) now recommends lenacapavir, a twice-yearly injectable drug, for HIV prevention, particularly for high-risk groups. This endorsement aims to expand prevention options. Lenacapavir, a long-acting capsid inhibitor, has shown high effectiveness in trials. The WHO's recommendation, announced at the International AIDS Society Conference, marks a shift from daily pills to long-acting protection, simplifying prevention. This new guidance comes amid concerns about funding for global HIV efforts. The WHO also streamlined testing protocols to support the drug's uptake, potentially impacting the fight against HIV/AIDS.